摘要
On December 8,2019,the first case of unexplained pneumonia was reported in China,in Wuhan,Hubei Province(1).By March 6,2020,over 100,000 confirmed cases of coronavirus disease 2019(COVID-19),and more than 3,400 deaths have been reported worldwide(data from National Health Commission of the People’s Republic of China,Official Channels of Hong Kong,Macao and Taiwan,and World Health Organization).COVID-19,which is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),is bound to have widespread ramifications on the clinical management system,organ transplantation being a prime example.Patients on the transplant waitlist are generally in poor condition.Moreover,post-transplant patients with weak immunity stemming from the long-term and regular administration of immunosuppressants are more likely to contract the SARS-CoV-2 infection than are healthy individuals.Thus,when considering transplant patient safety,balancing organ allocation principles with epidemic prevention and control is a dilemma for transplant teams.
基金
Supported by the 1.3.5 project for disciplines of excellence,West China Hospital,Sichuan University(No.ZY2017308)
the Major National Science and Technology Special Projects(No.2017ZX10203205-005-002 and 2017ZX10203205-001-004)
the National Natural Science Foundation of China(No.81470037 and 81770653).
